Lyell Immunopharma Inc
NASDAQ:LYEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lyell Immunopharma Inc
NASDAQ:LYEL
|
US |
|
Avalon Advanced Materials Inc
TSX:AVL
|
CA |
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
CA |
|
Neurogene Inc
NASDAQ:NGNE
|
US |
|
Impax Asset Management Group PLC
LSE:IPX
|
UK |
|
O
|
Opticept Technologies AB
STO:OPTI
|
SE |
|
C
|
China Star Food Group Ltd
SGX:42W
|
SG |
|
ANZ Group Holdings Ltd
OTC:ANZGF
|
AU |
Wall Street
Price Targets
LYEL Price Targets Summary
Lyell Immunopharma Inc
According to Wall Street analysts, the average 1-year price target for
LYEL
is 40.12 USD
with a low forecast of 34.34 USD and a high forecast of 47.25 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LYEL's stock price target?
Price Target
40.12
USD
According to Wall Street analysts, the average 1-year price target for
LYEL
is 40.12 USD
with a low forecast of 34.34 USD and a high forecast of 47.25 USD.
What is Lyell Immunopharma Inc's Revenue forecast?
Projected CAGR
1 043%
For the last 5 years the
compound annual growth rate for
Lyell Immunopharma Inc's revenue is
-66%.
The projected
CAGR
for the next 3 years is
1 043%.
